Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Developed by researchers in Australia, AOD-9604 was initially investigated as a potential anti-obesity drug due to its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat accumulation)
Further investigations to fully elucidate the effect of the V229A substitution on GLP-1R-cholesterol interactions might include detailed atomistic MD simulations of WT versus V229A receptors, as well as resolving cryo-EM structures of mutant and WT receptors in nanodiscs containing relevant lipid compositions to preserve receptor-lipid interactions in their native environment
For severe symptoms, attend A&E or call 999 if appropriate
Cell Metab (2013) 17(6):87382
Early bird tickets: $199 with code SUMMITEARLYBIRD at checkout
its also a common issue affecting older adults
US$ 26.43
US$ 26.73
US$ 23.38
US$ 25.70
US$ 29.02
